National and Kapodistrian University of Athens
Μεταβολές δεικτών φλεγμονής στην οξεία σωματική άσκηση υπερτασικών ασθενών: σημασία της αντιυπερτασικής αγωγής
Abstract
dc:descriptionArterial hypertension (AH) is an established risk factor for acute coronary syndromes whereas physical exertion may trigger the onset of such an event. The mechanisms involved include the rupture of a small, inflamed, coronary plaque and the activation of thrombogenic factors. Circulating inflammatory and thrombotic biomarkers are implicated in the pathophysiology of AH whereas blood pressure (BP)-lowering treatment has been associated with beneficial effects on subclinical inflammation and thrombosis. Purpose: This prospective study sought to evaluate the acute effect of exercise on inflammatory and thrombotic biomarkers‟ levels in hypertensive patients both before and after pharmaceutical BP normalization and to compare the effect of different antihypertensive drugs on the inflammatory and thrombotic response during exercise. Methods: The study comprised a total of 60 hypertensive patients (46.9 years, 65% males, office BP 141.4/94.0 mmHg) and 65 normotensive individuals (45.2 years, 60% males, office BP 117.1/74.5 mmHg) as a control group. Subjects with inflammatory or coronary artery disease were excluded from the study. Hypertensive patients were randomized to an angiotensin receptor blocker (ARB)- or non-dihydropyridine calcium channel blocker (CCB)-based regimen. A maximal, based on age, electrocardiographic treadmill exercise testing (Bruce protocol) was performed both in normotensives and in hypertensives (before treatment and 6 months after pharmaceutical BP normalization, office BP 118.4/77.4 mmHg). High-sensitivity C-reactive protein (hsCRP), serum amyloid A (SAA), white blood cells (WBC), tumor necrosis factor-a (TNF-α), interleukin-6 (IL-6), total fibrinogen (TF) and von Willebrand factor (vWF) levels, as well as plasminogen activator inhibitor-1 (PAI-1) activity were measured in blood samples taken while the patients were at rest and immediately after peak exercise.Results: Both in normotensives and in hypertensives (before and after pharmaceutical BP normalization) all biomarkers increased during exercise to a significant degree, except PAI-1, which decreased (P<0.05 for the difference between resting and peak exercise for all biomarkers). Untreated hypertensives had a greater exercise-induced percentage change compared to normotensives in hsCRP (8.6% vs. 7.7%), SAA (11.9% vs. 5.6%), WBC (51.7% vs. 45.0%) and PAI-1 (-20.1% vs. -17.3%), a less marked percentage change in TNF-α (4.5%161164vs. 8.5%) and vWF (24.9% vs. 30.6%) and a similar percentage change in IL-6 (23.0% vs. 23.8%) and TF (8.5% vs. 8.5%). After BP normalization they had a less marked exercise-induced percentage change compared to normotensives in hsCRP (6.8% vs. 7.7%), SAA (5.3% vs. 5.6%), vWF (29.0% vs. 30.6%) and PAI-1 (-10.5% vs. -17.3%) but a greater percentage change in WBC (49.0% vs. 45.0%), TNF-α (19.2% vs. 8.5%), IL-6 (39.3% vs. 23.8%) and TF (11.8% vs. 8.5%). The ARB group had a less marked exercise-induced percentage change than the CCB group in hsCRP (5.8% vs. 7.7%), SAA (4.2% vs. 7.2%), WBC (46.8% vs. 52.6%), TNF-α (16.3% vs. 24.3%), TF (9.5% vs. 16.9%) and PAI-1 (-9.5% vs. -12.3%) but a similar percentage change in IL-6 (39.4% vs. 38.6%) and vWF (29.2% vs. 28.6%). Conclusions: The acute inflammatory and thrombotic response during exercise (increase of hsCRP, SAA, WBC, TNF-α, IL-6, TF and vWF levels) is accompanied by a parallel “protective” fibrinolytic counter-regulation (decrease of PAI-1 activity) that is part of the acute phase response (APR) to exercise. Untreated hypertensives present with a rather more intense APR to exercise compared to normotensives whereas BP normalization leads to an exercise-induced APR closer to the normotensives‟ pattern. ARBs are most likely more effective than CCBs at suppressing the exercise-induced APR. Potential superiority of ARBs over CCBs at protecting hypertensive patients against exercise-related coronary events remains to be elucidated.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liakos, Charalampos
- Λιάκος, Χαράλαμπος
Subjects
dc:subject × 20- Βιοδείκτες φλεγμονής
- Βιοδείκτες θρόμβωσης
- Φλεγμονώδης και θρομβωτική απάντηση
- Απάντηση οξείας φάσης
- Οξεία σωματική άσκηση
- Αντιυπερτασική αγωγή
- Ιρβεσαρτάνη
- Διλτιαζέμη
- Inflammatory biomarkers
- Thrombotic biomarkers
- Inflammatory and thrombotic response
- Acute phase response (APR)
- Acute physical exercise
- Antihypertensive treatment
- Irbesartan
- Diltiazem
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40818